Trials / Unknown
UnknownNCT02935764
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) Versus Irinotecan Monodrug as Second-line Treatment in Metastatic Colorectal Cancer Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 164 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan | 180 mg/m2 iv gtt, d1 |
| DRUG | 5-fluorouracil | 5-FU 400mg/m2 iv, 2400mg/m2 civ 46h |
| DRUG | Leucovorin | 400mg/m2 iv gtt,d1 |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2019-10-01
- First posted
- 2016-10-17
- Last updated
- 2016-10-17
Source: ClinicalTrials.gov record NCT02935764. Inclusion in this directory is not an endorsement.